2966936-23-0
2966936-23-0
Chemical Structure
Biological Activity: Nesfrotamig (YH32367; ABL105) is a bispecific activator targeting HER2 and 4-1BB. Nesfrotamig has Kd values of 0.48 nM and 3.36 nM for human HER2 and human 4-1BB, respectively. Nesfrotamig blocks tumor cell growth signals, activates HER2-dependent tumor-localized 4-1BB to maintain T cell survival, and induces NK cell-mediated antibody-dependent cellular cytotoxicity, thereby enhancing the cytotoxicity and tumor infiltration capacity of immune cells. Nesfrotamig exhibits a favorable safety profile and is suitable for research on HER2-positive and HER2-low tumors[1][2][3].
| Art. -Nr. | Produktname | Reinheit | Beschreibung | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Nesfrotamig | 99.22% | Nesfrotamig (YH32367; ABL105) is a bispecific activator targeting HER2 and 4-1BB. Nesfrotamig has Kd values of 0.48 nM and 3.36 nM for human HER2 and human 4-1BB, respectively. Nesfrotamig blocks tumor cell growth signals, activates HER2-dependent tumor-localized 4-1BB to maintain T cell survival, and induces NK cell-mediated antibody-dependent cellular cytotoxicity, thereby enhancing the cytotoxicity and tumor infiltration capacity of immune cells. Nesfrotamig exhibits a favorable safety profile and is suitable for research on HER2-positive and HER2-low tumors. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Song M Y, et al. A novel HER2/4-1BB bispecific antibody, YH32367 (ABL105) shows potent anti-tumor effect through tumor-directed T cell activation[J]. Cancer Res, 2020, 80(16_Supplement): 6524-6524.
- [2]. Lee E, et al. 544P a novel HER2/4-1BB bispecific antibody, YH32367 (ABL105) exerts significant anti-tumor effects through tumor-directed T cell activation[J]. Annals of Oncology, 2021, 32: S607-S608.
- [3]. Lee E, et al. The HER2/4-1BB bispecific antibody, YH32367 (ABL105) demonstrates optimal efficacy and safety for HER2-expressing tumors and exhibits synergistic efficacy when combined with anti-PD-L1[J]. Cancer Research, 2024, 84(6_Supplement): 6354-6354.
